- Home
- PHUN vs APLT Comparison
PHUN vs APLT Comparison
Compare PHUN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- APLT
- Stock Information
- Founded
- PHUN 2009
- APLT 2016
- Country
- PHUN United States
- APLT United States
- Employees
- PHUN N/A
- APLT N/A
- Industry
- PHUN EDP Services
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- APLT Health Care
- Exchange
- PHUN Nasdaq
- APLT Nasdaq
- Market Cap
- PHUN 88.8M
- APLT 80.3M
- IPO Year
- PHUN N/A
- APLT 2019
- Fundamental
- Price
- PHUN $3.88
- APLT $0.61
- Analyst Decision
- PHUN Strong Buy
- APLT Buy
- Analyst Count
- PHUN 3
- APLT 7
- Target Price
- PHUN $13.00
- APLT $6.10
- AVG Volume (30 Days)
- PHUN 1.4M
- APLT 4.2M
- Earning Date
- PHUN 03-11-2025
- APLT 03-05-2025
- Dividend Yield
- PHUN N/A
- APLT N/A
- EPS Growth
- PHUN N/A
- APLT N/A
- EPS
- PHUN N/A
- APLT N/A
- Revenue
- PHUN $3,537,000.00
- APLT N/A
- Revenue This Year
- PHUN N/A
- APLT N/A
- Revenue Next Year
- PHUN $93.33
- APLT $2,622.90
- P/E Ratio
- PHUN N/A
- APLT N/A
- Revenue Growth
- PHUN N/A
- APLT N/A
- 52 Week Low
- PHUN $2.85
- APLT $0.54
- 52 Week High
- PHUN $17.99
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- PHUN 38.74
- APLT 27.17
- Support Level
- PHUN $3.71
- APLT $0.54
- Resistance Level
- PHUN $4.04
- APLT $0.66
- Average True Range (ATR)
- PHUN 0.27
- APLT 0.06
- MACD
- PHUN -0.06
- APLT 0.11
- Stochastic Oscillator
- PHUN 14.28
- APLT 40.99
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.